Anti-SARS-CoV-2 Recombinant Therapeutic Antibodies
This Competitive Intelligence report about Anti-SARS-CoV-2 Recombinant Therapeutic Antibodies describes the landscape of industry-driven approaches to discover and develop recombinant therapeutic antibodies against SARS-CoV-2 for treatment of COVID-19 as of August 28, 2020.
COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19. Since the outbreak of the SARS-CoV-2 pandemia, industry efforts rapidly have initiated work to repurpose existing biologic therapeutics and discover and develop novel antibody and protein candidates to treat COVID-19.
As of end of August of 2020, seven novel recombinant therapeutic monoclonal antibodies or antibody cocktails are in clinical development and further at least nine antibody-products are expected to enter clinical development, including recombinant polyclonal antibody preparations.
This report includes a compilation of industry-driven projects in research and development of SARS-CoV-2 targeted recombinant therapeutic antibodies for treatment of COVID-19. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.